<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3ASplenic_B-cell_Lymphoma%2FLeukemia%2C_Unclassifiable</id>
	<title>HAEM4:Splenic B-cell Lymphoma/Leukemia, Unclassifiable - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3ASplenic_B-cell_Lymphoma%2FLeukemia%2C_Unclassifiable"/>
	<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Splenic_B-cell_Lymphoma/Leukemia,_Unclassifiable&amp;action=history"/>
	<updated>2026-04-30T20:03:53Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.5</generator>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Splenic_B-cell_Lymphoma/Leukemia,_Unclassifiable&amp;diff=13248&amp;oldid=prev</id>
		<title>Bailey.Glen at 21:33, 4 December 2023</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Splenic_B-cell_Lymphoma/Leukemia,_Unclassifiable&amp;diff=13248&amp;oldid=prev"/>
		<updated>2023-12-04T21:33:21Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:33, 4 December 2023&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l10&quot;&gt;Line 10:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 10:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==General Disease Overview / Description of Cancer Category==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==General Disease Overview / Description of Cancer Category==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Splenic B-cell lymphoma/leukemia, Unclassifiable (SBLL-U) includes primary splenic lymphomas that cannot be better classified into other [[Mature B-Cell Neoplasms|mature B-cell neoplasms]] and are overall rare, accounting for &amp;lt;1% of lymphomas.  Two entities in this category, [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Hairy Cell Leukemia Variant&lt;/del&gt;|hairy cell leukemia variant]] (HCL-v) and [[Splenic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Diffuse Red Pulp Small &lt;/del&gt;B-cell &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoma&lt;/del&gt;|splenic diffuse red pulp small B-cell lymphoma]] (SDRPL) may represent distinct entities and are designated as provisional entities in the 2017 WHO.  Recent molecular evidence suggests that they are distinct from each other and from [[Splenic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Marginal Zone Lymphoma&lt;/del&gt;|splenic marginal zone lymphoma]] and [[Hairy &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Cell Leukemia&lt;/del&gt;|hairy cell leukemia]], which which the have overlapping clinical, morphologic, and immunophenotypic features.  Primary splenic lymphomas that cannot be classified as HCL-v or SDRPL should be classified as splenic B-cell lymphoma/leukemia, Unclassifiable.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Splenic B-cell lymphoma/leukemia, Unclassifiable (SBLL-U) includes primary splenic lymphomas that cannot be better classified into other [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM4:&lt;/ins&gt;Mature B-Cell Neoplasms|mature B-cell neoplasms]] and are overall rare, accounting for &amp;lt;1% of lymphomas.  Two entities in this category, [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli&lt;/ins&gt;|hairy cell leukemia variant]] (HCL-v) and [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Splenic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;diffuse red pulp small &lt;/ins&gt;B-cell &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoma&lt;/ins&gt;|splenic diffuse red pulp small B-cell lymphoma]] (SDRPL) may represent distinct entities and are designated as provisional entities in the 2017 WHO.  Recent molecular evidence suggests that they are distinct from each other and from [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Splenic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;marginal zone lymphoma&lt;/ins&gt;|splenic marginal zone lymphoma]] and [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Hairy &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cell leukaemia&lt;/ins&gt;|hairy cell leukemia]], which which the have overlapping clinical, morphologic, and immunophenotypic features.  Primary splenic lymphomas that cannot be classified as HCL-v or SDRPL should be classified as splenic B-cell lymphoma/leukemia, Unclassifiable.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Splenic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Diffuse Red Pulp Small &lt;/del&gt;B-cell &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lymphoma&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Splenic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;diffuse red pulp small &lt;/ins&gt;B-cell &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lymphoma&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Hairy Cell Leukemia Variant&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l21&quot;&gt;Line 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 21:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Differential diagnosis:  other small B-cell lymphomas with cytoplasmic projections and significant splenic involvement&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Differential diagnosis:  other small B-cell lymphomas with cytoplasmic projections and significant splenic involvement&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Splenic &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Marginal Zone Lymphoma&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Splenic &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;marginal zone lymphoma&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Hairy &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Cell Leukemia&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Hairy &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cell leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Additional Information==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Additional Information==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key wikidatabase:diff:1.41:old-12454:rev-13248:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Splenic_B-cell_Lymphoma/Leukemia,_Unclassifiable&amp;diff=12454&amp;oldid=prev</id>
		<title>Bailey.Glen: Created page with &quot;==Primary Author(s)*==  * Snehal Patel, MD, PhD __TOC__  ==Graphical Data Links==  * N/A  ==General Disease Overview / Description of Cancer Category==  Splenic B-cell lymphom...&quot;</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Splenic_B-cell_Lymphoma/Leukemia,_Unclassifiable&amp;diff=12454&amp;oldid=prev"/>
		<updated>2023-11-03T18:11:27Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Primary Author(s)*==  * Snehal Patel, MD, PhD __TOC__  ==Graphical Data Links==  * N/A  ==General Disease Overview / Description of Cancer Category==  Splenic B-cell lymphom...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Primary Author(s)*==&lt;br /&gt;
&lt;br /&gt;
* Snehal Patel, MD, PhD&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
==Graphical Data Links==&lt;br /&gt;
&lt;br /&gt;
* N/A&lt;br /&gt;
&lt;br /&gt;
==General Disease Overview / Description of Cancer Category==&lt;br /&gt;
&lt;br /&gt;
Splenic B-cell lymphoma/leukemia, Unclassifiable (SBLL-U) includes primary splenic lymphomas that cannot be better classified into other [[Mature B-Cell Neoplasms|mature B-cell neoplasms]] and are overall rare, accounting for &amp;lt;1% of lymphomas.  Two entities in this category, [[Hairy Cell Leukemia Variant|hairy cell leukemia variant]] (HCL-v) and [[Splenic Diffuse Red Pulp Small B-cell Lymphoma|splenic diffuse red pulp small B-cell lymphoma]] (SDRPL) may represent distinct entities and are designated as provisional entities in the 2017 WHO.  Recent molecular evidence suggests that they are distinct from each other and from [[Splenic Marginal Zone Lymphoma|splenic marginal zone lymphoma]] and [[Hairy Cell Leukemia|hairy cell leukemia]], which which the have overlapping clinical, morphologic, and immunophenotypic features.  Primary splenic lymphomas that cannot be classified as HCL-v or SDRPL should be classified as splenic B-cell lymphoma/leukemia, Unclassifiable.&lt;br /&gt;
&lt;br /&gt;
==WHO Classification Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
* [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]]&lt;br /&gt;
* [[Hairy Cell Leukemia Variant]]&lt;br /&gt;
&lt;br /&gt;
==Other Related Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
Differential diagnosis:  other small B-cell lymphomas with cytoplasmic projections and significant splenic involvement&lt;br /&gt;
&lt;br /&gt;
* [[Splenic Marginal Zone Lymphoma]]&lt;br /&gt;
* [[Hairy Cell Leukemia]]&lt;br /&gt;
&lt;br /&gt;
==Additional Information==&lt;br /&gt;
&lt;br /&gt;
* N/A&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===EXAMPLE Book===&lt;br /&gt;
&lt;br /&gt;
#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.&lt;br /&gt;
&lt;br /&gt;
==Notes==&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.&lt;/div&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
</feed>